Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 126.00% | -881.58% | -428.89% | 36.73% | 31.46% |
| Total Depreciation and Amortization | 23.18% | 26.24% | 20.42% | -6.29% | -13.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,797.58% | 3,269.19% | 1,648.77% | -142.50% | -7.81% |
| Change in Net Operating Assets | 102.75% | 57.62% | -112.27% | 71.15% | -145.88% |
| Cash from Operations | 23.13% | 37.52% | -7.01% | 15.51% | -5.43% |
| Capital Expenditure | -9.32% | 89.29% | 72.00% | -155.26% | -301.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -597.83% | -100.00% | 100.00% | -- | -69.49% |
| Cash from Investing | -681.94% | -100.31% | 99.84% | 5,107.89% | -72.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.14% | -23.08% | 0.00% | -7.69% | -7.69% |
| Issuance of Common Stock | -6.95% | 20,720.00% | -- | -62.32% | -- |
| Repurchase of Common Stock | -- | -- | -- | 34.78% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -185.93% |
| Cash from Financing | -6.23% | 61,233.33% | -392.38% | -64.03% | 167,284.62% |
| Foreign Exchange rate Adjustments | 620.00% | -110.53% | 432.95% | -4.29% | -91.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.08% | 3.54% | 60.10% | -75.55% | 352.10% |